ZyVersa Research Development from 2010 to 2026
| ZVSA Stock | 0.24 0.01 4.35% |
Research Development | First Reported 2010-12-31 | Previous Quarter 2 B | Current Value 2.1 B | Quarterly Volatility 783.1 M |
Check ZyVersa Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ZyVersa Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.8 K, Interest Expense of 398.8 K or Selling General Administrative of 8.9 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.13. ZyVersa financial statements analysis is a perfect complement when working with ZyVersa Therapeutics Valuation or Volatility modules.
ZyVersa | Research Development | Build AI portfolio with ZyVersa Stock |
Analyzing ZyVersa Therapeutics's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing ZyVersa Therapeutics's current valuation and future prospects.
Latest ZyVersa Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of ZyVersa Therapeutics over the last few years. It is ZyVersa Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ZyVersa Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
ZyVersa Research Development Regression Statistics
| Arithmetic Mean | 356,224,311 | |
| Geometric Mean | 15,803,600 | |
| Coefficient Of Variation | 219.83 | |
| Mean Deviation | 577,087,398 | |
| Median | 6,468,887 | |
| Standard Deviation | 783,096,228 | |
| Sample Variance | 613239.7T | |
| Range | 2.1B | |
| R-Value | 0.66 | |
| Mean Square Error | 365651.2T | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 102,983,282 | |
| Total Sum of Squares | 9811835.2T |
ZyVersa Research Development History
About ZyVersa Therapeutics Financial Statements
ZyVersa Therapeutics stakeholders use historical fundamental indicators, such as ZyVersa Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Although ZyVersa Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ZyVersa Therapeutics' assets and liabilities are reflected in the revenues and expenses on ZyVersa Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ZyVersa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 2 B | 2.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out the analysis of ZyVersa Therapeutics Correlation against competitors. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. Anticipated expansion of ZyVersa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ZyVersa Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate ZyVersa Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating ZyVersa Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause ZyVersa Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, ZyVersa Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.